Abstract
It is a propitious time to consider drugs for the treatment of congestive heart failure (CHF). There is at present a great deal of academic and commercial interest in such agents, perhaps reflecting an early success, Captopril, and a partial success, amrinone IV, after a good deal of ambiguity and failure with prazosin and the beta agonists. Yet there is still a great deal to be learned. We do not yet know how much it is possible to achieve or what hemodynamic or exercise responses to drugs correspond best to clinically meaningful improvement.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Temple, R. (1987). Design of Trials to Assess Safety and Effectiveness in Rx of CHF. In: Morganroth, J., Moore, E.N. (eds) Congestive Heart Failure. Developments in Cardiovascular Medicine, vol 75. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2077-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2077-7_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9232-6
Online ISBN: 978-1-4613-2077-7
eBook Packages: Springer Book Archive